These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 23171332)
1. Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics. Kuypers DR Pharmacogenomics; 2012 Nov; 13(15):1679-83. PubMed ID: 23171332 [No Abstract] [Full Text] [Related]
2. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Woillard JB; Kamar N; Rousseau A; Rostaing L; Marquet P; Picard N Pharmacogenet Genomics; 2012 Oct; 22(10):725-32. PubMed ID: 22863900 [TBL] [Abstract][Full Text] [Related]
5. Sirolimus to replace calcineurin inhibitors? Too early yet. Cravedi P; Ruggenenti P; Remuzzi G Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662 [No Abstract] [Full Text] [Related]
6. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Stallone G; Infante B; Pontrelli P; Gigante M; Montemurno E; Loverre A; Rossini M; Schena FP; Grandaliano G; Gesualdo L Transplantation; 2011 May; 91(9):997-1004. PubMed ID: 21364499 [TBL] [Abstract][Full Text] [Related]
7. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335 [TBL] [Abstract][Full Text] [Related]
8. The pros and the cons of mTOR inhibitors in kidney transplantation. Ponticelli C Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908 [TBL] [Abstract][Full Text] [Related]